FDA mulls relaxing rules for unproven peptide therapies championed by RFK Jr.
The FDA is weighing loosening restrictions on certain peptide therapies promoted by RFK Jr., which could expand access to unproven treatments while sparking concerns about safety, efficacy, and how such therapies are marketed.